CD8A and neoplasm: verified that radiotherapy combined with anti-CD25/CTLA4 monoclonal antibody could reduce Tregs, PD1+CD8+ and PD1+CD4+ T cells and effectively mount the anti-tumor response, inhibiting the growth of local and distal unirradiated tumors (154).